Evidence map›Paper›PMID 40694139›Full record

ArticleJournal of cancer research and clinical oncology2025

Clinical characteristics and treatment evaluation of diffuse large B-cell lymphoma in Chinese children and adolescents: a multicenter clinical study of China-Net childhood lymphoma group B-NHL-2017.

Yang Fu, Ling Jin, Yanlong Duan, Jing Yang, Ying Liu, Bo Hu, Mincui Zheng, Yunpeng Dai, Ansheng Liu, Wei Liu and 16 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Yang Fu *Department of Hematology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, 201102, China.ORCID http://orcid.org/0000-0002-0378-2410
Ling Jin *Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China.
Yanlong Duan *Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China.
Jing YangMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China.
Ying LiuDepartment of Pediatric Lymphoma, Beijing Gobroad Boren Hospital, Beijing, 100070, China.
Bo HuDepartment of Pediatric Lymphoma, Beijing Gobroad Boren Hospital, Beijing, 100070, China.
Mincui ZhengDepartment of Hematology and Oncology, Hunan Children's Hospital, Changsha, 410007, China.
Yunpeng DaiDepartment of Pediatrics, Shandong Provincial Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
Ansheng LiuDepartment of Hematology and Oncology, National Children's Regional Medical Center (Northwest), The Affiliated Children Hospital of Xi'an Jiaotong University, Xi'an Children's Hospital, Xi'an, 710002, China.
Wei LiuDepartment of Hematology and Oncology, Beijing Children's Hospital, National Children's Regional Medical Center, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou Hospital, Children's Hospital Affiliated of Zhengzhou University, Zhengzhou, 450012, China.
Leping ZhangDepartment of Pediatrics, Peking University People's Hospital, Beijing, 100044, China.
Fu LiDepartment of Hematology and Oncology, Jinan Children's Hospital, Children's Hospital Affiliated to Shandong University, Jinan, 250022, China.
Baoxi ZhangDepartment of Pediatrics, The Second Hospital of Hebei Medical University, Shijiazhuang, 050004, China.
Xiaojun YuanDepartment of Pediatric Hematology/Oncology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China.
Lirong SunDepartment of Pediatric Hematology and Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Rong LiuDepartment of Hematology, Capital Institute of Pediatrics, Children's Hospital, Capital Institute of Pediatrics, Beijing, 100020, China.
Zhuoyu WenDepartment of Pediatric Hematology and Oncology, Northwest Women's and Children's Hospital, Shaanxi Maternal and Child Health Hospital, Xi'an, 710061, China.
Runming JinDepartment of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Shuquan ZhuangDepartment of Pediatrics, Quanzhou First Hospital, Fujian Medical University, Fujian, Quanzhou, 362002, China.
Lian JiangDepartment of Pediatrics, Hebei Tumor Hospital, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Yufeng LiuDepartment of Hematology and Oncology, Children's Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Haixia ZhouDepartment of Pediatric Hematology, The Second Affiliated Hospital of Wenzhou Medical University, Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, China.
Chen ShenDepartment of Hematology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, 201102, China.
Hongsheng WangDepartment of Hematology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, 201102, China. honswang@hotmail.com.ORCID http://orcid.org/0000-0003-0831-9641
Yonghong ZhangMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China. zhangyongh@gobroadhealthcare.com.
Xiaowen ZhaiDepartment of Hematology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, 201102, China. xwzhai@fudan.edu.cn.

Funding

Fudan University Education Development Foundation ZSBK0046the Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center SHDC12019121the Cyrus Tang Foundation ZSBK0070the Major Projects Program of Shanghai Municipal Committee of Science and Technology 21Y31900302the National Natural Science Foundation of China 82141125
6 · The paper itself

Abstract

backgroundChina-Net Childhood Lymphoma (CNCL) group B-NHL-2017 study is a prospective multi-center study in China, with the purpose of standardizing the diagnosis and treatment of childhood lymphoma, and improving the prognosis.

methodsFrom May 2017 to June 2023, 20 centers participated in the diffuse large B-cell lymphoma (DLBCL) study. The clinical data were analyzed to summarize the clinical characteristics, treatment response and outcome. The primary endpoint was 5-year event-free survival (EFS). The trial is registered with the Chinese Clinical Trial Registry (ChiCTR1800020067).

resultsA total of 138 children and adolescents were enrolled, including 101 males and 37 females. The median age of disease diagnosis was 9.0 years (range: 2.3-15.5 years). The range of follow-up time was 17 d-6.0 years. A total of 12 events occurred in this study, including 7 deaths. of which 4 patients died of disease and chemotherapy comorbidities (severe infection, septic shock, etc.), 1 died of disease progression (enlargement of the primary tumor and tumor metastasis), 1 died of recurrence, and 1 died of severe pneumonia in the third year after completing all chemotherapy courses. Recurrence occurred in 6 (4.3%) patients at 14.9 months (range: 4.4-32.6 months) after initial treatment. The 5-year overall survival (OS) was 90.7 ± 5.0% and the 5-year EFS was 85.5 ± 5.4%. Based on Cox regression analysis, no Rituximab during treatment is an independent risk factor for mortality in patients with DLBCL.

conclusionThe efficacy of CNCL-B-NHL-2017 protocol in the treatment of DLBCL in children and adolescents is close to results of international studies.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseAdolescentChildChild, PreschoolChinaCyclophosphamideEast Asian PeopleFemaleHumansMalePrognosisProspective StudiesRituximabSurvival RateCyclophosphamideRituximabChemotherapyChildDiffuse large B-cell lymphomaPrognosisTreatment

Identifiers

PMID40694139
PMCPMC12283495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.